Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (401)	9/5/2001 2:45:18 AM
From: tuck	Read Replies (1) \| Respond to of 1005

Bernard, ARNA's last guidance said cash flow positive this year and next, and that they were in the "financial consideration for technology" stage of discussion with three multi-national pharmas. Since then, the stock has had a lot of unannounced bad news priced into it. If it's even worse than the Street thinks, then I've made another bad entry. But BLUE HP intends to hold ARNA long term unless something comes along to obviate their technology. Anybody seeing any sign of this? Or feel the research premium is too high for what they've got? Cheers, Tuck